News
Featured Articles
Cristalia products with Nemera’s reusable pen injector commercialized in Brazil.
30/01/2024
Cristalia’s human growth hormone will be administered with CRISPEN®. Approved by ANVISA1, CRISPEN® is part of Nemera’s state-of-the-art pen injector platform PENDURA AD.
Continue ReadingLeveraging Nemera’s scientific expertise and continued effort in the nose-to-brain field
28/11/2023
Know more about the treatment area of Nose to brain that Nemera can offer
Continue ReadingThe Gender Equality Index at Nemera – Year 2023
28/02/2024
The Index, is calculated from 4 to 5 indicators depending on whether the company has less or more than 250 employees and takes into account
Continue ReadingBrand new state-of-the-art Nemera offices inaugurated in Lyon
12/09/2022
Located in the bio district of Gerland, the BREEAM certified collaborative space will house Nemera’s headquarters & European innovation teams. Morning coffee on the rooftop taking in a view ...
Continue ReadingThe Gender Equality Index at Nemera – Year 2021
25/02/2022
L’Index, se calcule à partir de 4 à 5 indicateurs selon que l’entreprise fait moins ou plus de 250 salariés et prend en compte : L’écart de rémunération femmes-hommes, L’é...
Continue ReadingNemera to build state-of-the-art manufacturing facility in Poland to serve more customers and patients
16/11/2021
Based in Szczecin, this facility extends Nemera’s manufacturing capabilities and will bring more drug delivery device solutions to patients. Following the dynamic growth of the drug delivery devices market, ...
Continue Reading